Eisai to Present Latest Data on Lemborexant and Perampanel at the 2019 American Academy of Neurology Annual Meeting

TOKYO, May 2, 2019 /PRNewswire/ -- Eisai Co., Ltd. (headquartered in Tokyo, Japan; current President: Haruo Naito; hereinafter referred to as "Eisai")Announced on April 24,The latest data on its dual orexin receptor antagonist, lemborexant, and its antiepileptic drug perampanel (Chinese brand name: Weiketai) will be presented at the 2019 Annual Meeting of the American Academy of Neurology (AAN). The meeting will be held from May 4 to 10, 2019, in Philadelphia, Pennsylvania, USA.

Eisai will deliver an oral presentation on the residual effects of lemborexant the following morning, based on the results of three placebo-controlled, active comparator-controlled, randomized, double-blind clinical studies conducted by the company. These studies assessed patients’ driving ability and postural stability upon awakening, as well as their performance in memory and attention tasks.

A total of 18 poster presentations on perampanel were featured, including the final analysis results of the Phase III clinical trial (Study 311) conducted in pediatric epilepsy patients aged 4 to 12 years, as well as an analysis of hospitalization risks in epilepsy patients before and after receiving perampanel treatment.

Eisai focuses on neurology as its core therapeutic area, striving to maximize the value of Lemborexant and Perampanel to further meet the diverse needs of patients and their families and enhance their well-being.

Oral Presentation:

Report Number and Report Date (Local Time)

Abstract Title

No.46Field: New Trends in Sleep Science and Therapy
5Month9Thursday
Poster Presentation:13:00 -15:00

Morning Effects of Lemborexant: Results from Three Randomized Studies

Poster Presentation:

Poster Number and Presentation Schedule (Local Time)

Abstract Title

Poster Number:5-009

Poster Exhibition:P1

Symptoms and Impact of Epilepsy: Qualitative Interview Results from Patients

5Month5Sunday

Poster Presentation:17:30～18:30

Poster Number and Presentation Schedule (Local Time)

Abstract Title

Poster Number:5-021

Perampanel as Add-on Therapy in Younger Children (Aged 4 to <7 Years)

Poster Exhibition:P1

and partial seizures of epilepsy in older children (aged 7 to under 12 years)

5Month5Sunday

Safety and Efficacy in Primary Generalized Tonic-Clonic Seizures: Final Results from

Poster Presentation:17:30～18:30

Study 311 Core Study

Poster Number:5-024

Poster Exhibition:P1

Post-Marketing Observational Study: Evaluation of Perampanel as Adjunctive Therapy in Patients with Epilepsy Aged 12 Years and Older

5Month5Sunday

Safety and Tolerability

Poster Presentation:17:30～18:30

Poster Number:5-029

Poster Exhibition:P1

Pharmacokinetic Evaluation of Intravenous Perampanel as a Bioequivalent Alternative to Oral Tablets

5Month5Sunday

Poster Presentation:17:30～18:30

Poster Number:5-001
Poster Exhibition:P3
5Month7Tuesday
Poster Presentation:17:30～18:30

Perampanel as Add-on Therapy in Pediatric Patients (Aged 4 to <12 Years)

Safety and Efficacy in Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures: Final Results of the 311 Core Study

Poster Number:5-002

Poster Exhibition:P3

Patients with uncontrolled epilepsy receiving

5Month7Tuesday

Hospitalization Risk Associated with Add-on Therapy of Long- versus Short-Half-Life Antiepileptic Drugs

Poster Presentation:17:30～18:30

Poster Number:5-005
Poster Session:P3
5Month7Tuesday
Poster Presentation:17:30～18:30

Application of Perampanel in Refractory, Drug-Resistant, and Super-Refractory Status Epilepticus: A Case Series from Austria, Finland, Germany, and Spain

Poster Number:5-007
Poster Session:P3
5Month7Tuesday
Poster Presentation:17:30-18:30

Impact of Concomitant Enzyme-Inducing Antiepileptic Drugs on the Safety and Efficacy of Perampanel as Adjunctive Therapy in Patients Aged 4 to <12 Years with Partial-Onset Seizures: Final Results of Study 311

Poster Number:5-017
Poster Session:P3
5Month7Tuesday
Poster Presentation:17:30-18:30

Phase II Open-Label Pharmacokinetic Study of Perampanel Oral Suspension as Adjunctive Therapy in Pediatric Patients with Epilepsy (Aged ≥1 Month to <24 Months): Design and Preliminary Safety Data of Study 238

Poster Number:5-018

Poster Exhibition:P3

Hospitalization Rates in Epilepsy Patients Treated with Perampanel or Lacosamide

5Month7Tuesday

Poster Presentation:17:30～18:30

Poster Number:5-019

410 Update on Subject Recruitment for the Study:

Poster Exhibition:P3

Perampanel as Monotherapy or as the Preferred Add-on Therapy

5Month7Tuesday

Partial Seizures (POS) or Primary Generalized Tonic-Clonic Seizures

Poster Presentation:17:30～18:30

Multicenter, Open-Label Phase IV Study

Poster Number:5-022

Poster Exhibition:P3

Patients with Epilepsy

5Month7Tuesday

Analysis of Hospitalization Risk Before and After Perampanel Treatment

Poster Presentation:17:30～18:30

Poster Number:5-027

Poster Exhibition:P3

Increased Healthcare Burden in Patients with Active Generalized Tonic-Clonic Seizures

5Month7Tuesday

Poster Presentation:17:30～18:30

Poster Numbers and Presentation Schedule (Local Time)

Abstract Title

Poster Number:5-004

Poster Exhibition:P5

Add-on Therapy with Perampanel in Pediatric Patients with Epilepsy: Population

5Month9Thursday

Pharmacokinetics (PK) and Exposure-Response Analysis

Poster Presentation:17:30～18:30

Poster Number:5-008

Poster Exhibition:P5

Application of Perampanel in Real-World Clinical Care for Patients with Epilepsy:

5Month9Thursday

Retrospective Phase IV Study 506 – Second Interim Analysis

Poster Presentation:17:30～18:30

Poster Number:5-009
Poster Session:P5
5Month9Thursday
Poster Presentation:17:30-18:30

Study 506 – Second Interim Analysis of a Retrospective Phase IV Study on the Use of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Pediatric Subgroup (Aged <12 Years)

Poster Number:5-014

Poster Exhibition:P5

Analysis of Hospitalization Risk Before and After Perampanel Treatment in Medicaid Patients with Epilepsy

5Month9Thursday

Poster Presentation:17:30-18:30

Poster Number:5-017
Poster Exhibition:P5
5Month9Thursday
Poster Presentation:17:30～1830

Study 506 – Second Interim Analysis of a Retrospective Phase IV Study on the Use of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Adolescent Subgroup (Aged 12 to <18 Years)